Investors & Media
Anna Protopapas is president and chief executive officer of Mersana Therapeutics, a clinical-stage antibody drug conjugate company, which she joined in March 2015.
Prior to Mersana, Ms. Protopapas was president of Millennium Pharmaceuticals, where she led Takeda Pharmaceutical Co.’s $1.3 billion oncology business. Ms. Protopapas also served as the executive vice president of global business development for Takeda Pharmaceuticals, where she was responsible for global acquisitions, partnering, licensing, and venture investing. In this role, she led Takeda’s $12 billion acquisition of Nycomed, a critical step in the company’s globalization. Ms. Protopapas was a member of Takeda’s executive committee and was elected a corporate officer in 2011. Earlier, Ms. Protopapas was an executive officer at Millennium Pharmaceuticals and served in various senior leadership positions, playing an integral role in the company’s transformation from a genomics start-up to a fully integrated oncology leader.
Anna has served on the board of directors of Ariad Pharmaceuticals from May 2015 to February 2017 when it was sold to Takeda for $5.2 billion. Anna also served on the board of Bioverativ from January 2017 to January 2018 when it was sold to Sanofi for $11.6 billion. She earned her bachelor’s degree in science and engineering from Princeton University, a master’s degree in chemical engineering practice from the Massachusetts Institute of Technology, and an MBA from Stanford Graduate School of Business.